278 related articles for article (PubMed ID: 21968357)
1. Reduction in fluoroquinolone use following introduction of ertapenem into a hospital formulary is associated with improvement in susceptibility of Pseudomonas aeruginosa to group 2 carbapenems: a 10-year study.
Cook PP; Gooch M; Rizzo S
Antimicrob Agents Chemother; 2011 Dec; 55(12):5597-601. PubMed ID: 21968357
[TBL] [Abstract][Full Text] [Related]
2. Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence.
Nicolau DP; Carmeli Y; Crank CW; Goff DA; Graber CJ; Lima AL; Goldstein EJ
Int J Antimicrob Agents; 2012 Jan; 39(1):11-5. PubMed ID: 22047702
[TBL] [Abstract][Full Text] [Related]
3. Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals.
Eagye KJ; Nicolau DP
Infect Control Hosp Epidemiol; 2010 May; 31(5):485-90. PubMed ID: 20334550
[TBL] [Abstract][Full Text] [Related]
4. Decreased resistance of Pseudomonas aeruginosa with restriction of ciprofloxacin in a large teaching hospital's intensive care and intermediate care units.
Lewis GJ; Fang X; Gooch M; Cook PP
Infect Control Hosp Epidemiol; 2012 Apr; 33(4):368-73. PubMed ID: 22418632
[TBL] [Abstract][Full Text] [Related]
5. Impact of ertapenem use on Pseudomonas aeruginosa and Acinetobacter baumannii imipenem susceptibility rates: collateral damage or positive effect on hospital ecology?
Sousa D; Castelo-Corral L; Gutiérrez-Urbón JM; Molina F; López-Calviño B; Bou G; Llinares P
J Antimicrob Chemother; 2013 Aug; 68(8):1917-25. PubMed ID: 23557925
[TBL] [Abstract][Full Text] [Related]
6. The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study.
Lima AL; Oliveira PR; Paula AP; Dal-Paz K; Rossi F; Zumiotti AV
Infect Control Hosp Epidemiol; 2009 May; 30(5):487-90. PubMed ID: 19335227
[TBL] [Abstract][Full Text] [Related]
7. Introduction of ertapenem into a hospital formulary: effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa.
Goldstein EJ; Citron DM; Peraino V; Elgourt T; Meibohm AR; Lu S
Antimicrob Agents Chemother; 2009 Dec; 53(12):5122-6. PubMed ID: 19786596
[TBL] [Abstract][Full Text] [Related]
8. Hand hygiene, and not ertapenem use, contributed to reduction of carbapenem-resistant Pseudomonas aeruginosa rates.
Pires dos Santos R; Jacoby T; Pires Machado D; Lisboa T; Gastal SL; Nagel FM; Kuplich NM; Konkewicz L; Gorniak Lovatto C; Pires MR; Goldani LZ
Infect Control Hosp Epidemiol; 2011 Jun; 32(6):584-90. PubMed ID: 21558771
[TBL] [Abstract][Full Text] [Related]
9. Does ertepenem alter the susceptibility of Pseudomonas aeruginosa to carbapenems?
Beović B; Kreft S; Seme K; Cizman M
J Chemother; 2011 Aug; 23(4):216-20. PubMed ID: 21803699
[TBL] [Abstract][Full Text] [Related]
10. Effect of a program to reduce hospital ciprofloxacin use on nosocomial Pseudomonas aeruginosa susceptibility to quinolones and other antimicrobial agents.
Cook PP; Das TD; Gooch M; Catrou PG
Infect Control Hosp Epidemiol; 2008 Aug; 29(8):716-22. PubMed ID: 18590455
[TBL] [Abstract][Full Text] [Related]
11. Association of ertapenem and antipseudomonal carbapenem usage and carbapenem resistance in Pseudomonas aeruginosa among 12 hospitals in Queensland, Australia.
McDougall DA; Morton AP; Playford EG
J Antimicrob Chemother; 2013 Feb; 68(2):457-60. PubMed ID: 23027714
[TBL] [Abstract][Full Text] [Related]
12. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
[TBL] [Abstract][Full Text] [Related]
13. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan.
Hsueh PR; Chen WH; Luh KT
Int J Antimicrob Agents; 2005 Dec; 26(6):463-72. PubMed ID: 16280243
[TBL] [Abstract][Full Text] [Related]
14. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
Master RN; Clark RB; Karlowsky JA; Ramirez J; Bordon JM
Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for hospital-acquired bacteremia due to carbapenem-resistant Pseudomonas aeruginosa in a Colombian hospital.
Valderrama SL; González PF; Caro MA; Ardila N; Ariza B; Gil F; Álvarez C
Biomedica; 2016 Feb; 36(0):69-77. PubMed ID: 27622627
[TBL] [Abstract][Full Text] [Related]
16. Impact of susceptibility profiles of Gram-negative bacteria before and after the introduction of ertapenem at a medical center in northern Taiwan from 2004 to 2010.
Lee CM; Lai CC; Wang YY; Lee MC; Hsueh PR
Diagn Microbiol Infect Dis; 2013 Jan; 75(1):94-100. PubMed ID: 23116904
[TBL] [Abstract][Full Text] [Related]
17. Carbapenem stewardship: positive impact on hospital ecology.
Lima AL; Oliveira PR; Paula AP; Dal-Paz K; Almeida JN; Félix Cda S; Rossi F
Braz J Infect Dis; 2011; 15(1):1-5. PubMed ID: 21412581
[TBL] [Abstract][Full Text] [Related]
18. Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.
Kresken M; Körber-Irrgang B; Korte-Berwanger M; Pfennigwerth N; Gatermann SG; Seifert H;
Int J Antimicrob Agents; 2020 Jun; 55(6):105959. PubMed ID: 32325200
[TBL] [Abstract][Full Text] [Related]
19. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
Jones RN; Kirby JT; Beach ML; Biedenbach DJ; Pfaller MA
Diagn Microbiol Infect Dis; 2002 Jul; 43(3):239-43. PubMed ID: 12106958
[TBL] [Abstract][Full Text] [Related]
20. Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa.
Muramatsu H; Horii T; Takeshita A; Hashimoto H; Maekawa M
Chemotherapy; 2005 May; 51(2-3):70-5. PubMed ID: 15870499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
